Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52664 | 0.87 | CYP2C9 (0.55) | CYP2C9KCNH2SMN1; SMN2NPSR1MEN1 | |
| SCHEMBL416290 | 0.87 | KCNH2 (0.39) | CYP2C9KCNH2SMN1; SMN2GLANPSR1 | |
| SCHEMBL10143664 | 0.86 | KCNH2 (0.40) | CYP2C9KCNH2SMN1; SMN2GLANPSR1 | |
| Hydrochloric Acid SCHEMBL420291 | 0.85 | KCNH2 (0.39) | CYP2C9KCNH2SMN1; SMN2GLANPSR1 | |
| SCHEMBL10144297 | 0.85 | KCNH2 (0.41) | CYP2C9KCNH2SMN1; SMN2GLANPSR1 | |
| Hydrochloric Acid SCHEMBL418376 | 0.84 | KCNH2 (0.41) | CYP2C9KCNH2SMN1; SMN2GLANPSR1 | |
| SCHEMBL64360 | 0.83 | CYP2C9 (0.40) | CYP2C9KCNH2SMN1; SMN2NPSR1LMNA | |
| SCHEMBL63588 | 0.83 | CYP2C9 (0.54) | CYP2C9KCNH2SMN1; SMN2NPSR1MEN1 | |
| SCHEMBL52540 | 0.81 | CYP2C9 (0.49) | CYP2C9KCNH2SMN1; SMN2NPSR1MEN1 | |
| SCHEMBL9921566 | 0.81 | CYP2C9 (0.34) | CYP2C9KCNH2TP53HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | CYP2C9 1960/4885KCNH2 2502/4885SMN1; SMN2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.